Dec 6, 2024
We are proud to announce the launch of Nanomics’ 12K Plasma Proteome Database, the largest human plasma proteome database ever released using our proprietary Proteonano™ Ultraplex Proteomics Platform.
Hangzhou, 6 December 2024: We are proud to announce the launch of Nanomics’ 12K Plasma Proteome Database, the largest human plasma proteome database ever released using our proprietary Proteonano™️ Ultraplex Proteomics Platform.
This milestone achievement represents a significant advancement in plasma proteomics, providing unparalleled insights into the human proteome. With data covering 12,273 proteins, our database achieves over 65% coverage of major existing proteomics databases. This extensive coverage, combined with the unmatched dynamic range and precision of our Proteonano™️ platform, positions this resource as a key tool for researchers in various fields, including biomarker discovery, disease diagnostics, and precision medicine.
Key Features and Advancements:
Unprecedented Data Coverage: Our 12K Plasma Proteome Database includes a comprehensive list of 12,273 proteins, significantly expanding the breadth of knowledge available in the field of plasma proteomics.
High Dynamic Range and Precision: Proteonano™️’s ultra-plex technology ensures high sensitivity and precision, enabling the detection of both high-abundance and low-abundance proteins with unmatched accuracy.
Benchmark for Plasma Proteomics Research: This database sets a new standard for plasma proteomics, offering researchers a robust, high-quality resource to drive discovery and innovation in biomedical research.
A Game-Changer for Plasma Proteomics
The release of this database is a pivotal moment in the field of plasma proteomics, as it provides researchers and clinicians with a powerful tool to further explore the human plasma proteome. By offering such extensive protein coverage and high-quality data, Nanomics aims to accelerate the identification of new biomarkers, improve diagnostic capabilities, and enable personalized therapeutic strategies.
Dr. Wu Hao, CEO of Nanomics Biotech, commented on the release: "With the launch of our 12K Plasma Proteome Database, we are providing the research community with an invaluable resource that will help drive advancements in proteomics and precision medicine. Our commitment to delivering cutting-edge technology and high-quality data is stronger than ever, and we look forward to seeing the impact this database will have on scientific discovery and clinical applications."
What This Means for the Future of Proteomics Research
The 12K Plasma Proteome Database is more than just a compilation of protein data; it is a key enabler for the next generation of biomedical research. Whether it’s identifying novel biomarkers for disease detection or exploring new therapeutic targets, this database is a crucial asset for anyone working in proteomics, biomarker research, or clinical diagnostics.
We are confident that this breakthrough will significantly enhance the depth and scope of plasma proteomics studies, helping to address some of the most pressing challenges in human health and disease.